$4.50
5.37% today
Nasdaq, Sep 04, 05:20 pm CET
ISIN
US74017N1054
Symbol
PGEN

Precigen Inc Stock price

$4.75
+2.99 169.89% 1M
+3.08 184.43% 6M
+3.63 324.11% YTD
+3.69 348.11% 1Y
+2.37 99.58% 3Y
-0.74 13.48% 5Y
-36.06 88.36% 10Y
-18.86 79.89% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
-0.01 0.21%
ISIN
US74017N1054
Symbol
PGEN
Industry

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$1.4b
Net debt
positive
Cash
$59.8m
Shares outstanding
297.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
326.1 | 102.0
EV/Sales
312.4 | 97.7
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
45.9%
Return on Equity
-189.2%
ROCE
-120.0%
ROIC
-249.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$4.3m | $13.9m
EBITDA
$-91.9m | $-103.0m
EBIT
$-94.5m | $-103.8m
Net Income
$-124.5m | $-121.5m
Free Cash Flow
$-69.8m
Growth (TTM | estimate)
Revenue
-1.1% | 253.2%
EBITDA
-3.7% | -14.2%
EBIT
0.6% | -9.6%
Net Income
8.0% | 3.7%
Free Cash Flow
10.5%
Margin (TTM | estimate)
Gross
-0.7%
EBITDA
-2,116.5% | -742.2%
EBIT
-2,176.3%
Net
-2,868.7% | -875.5%
Free Cash Flow
-1,607.7%
More
EPS
$-0.4
FCF per Share
$-0.2
Short interest
17.9%
Employees
143
Rev per Employee
$30.0k
Show more

Is Precigen Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Precigen Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Precigen Inc forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Precigen Inc forecast:

Buy
80%
Hold
20%

Financial data from Precigen Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
4.34 4.34
1% 1%
100%
- Direct Costs 4.37 4.37
12% 12%
101%
-0.03 -0.03
95% 95%
-1%
- Selling and Administrative Expenses 49 49
24% 24%
1,137%
- Research and Development Expense 45 45
17% 17%
1,039%
-92 -92
4% 4%
-2,117%
- Depreciation and Amortization 2.59 2.59
60% 60%
60%
EBIT (Operating Income) EBIT -94 -94
1% 1%
-2,176%
Net Profit -125 -125
8% 8%
-2,869%

In millions USD.

Don't miss a Thing! We will send you all news about Precigen Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Precigen Inc Stock News

Neutral
PRNewsWire
one day ago
$100 million funded at close fortifies balance sheet and supports robust US commercialization of PAPZIMEOS, as well as potential expansion into international markets and the pursuit of pediatric and other HPV-related indications GERMANTOWN, Md. , Sept. 2, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medic...
Neutral
Seeking Alpha
2 days ago
Precigen, Inc. - Special Call Company Participants Helen Sabzevari - President, CEO & Director Phil Tennant - Chief Commercial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Presentation Swayampakula Ramakanth MD of Equity Research & Senior Healthcare Analyst Greetings, and thanks for joining us to have a conversation with Helen Sabzev...
Neutral
PRNewsWire
10 days ago
GERMANTOWN, Md. , Aug. 25, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that Precigen will participate in two upcoming virtual fireside chats hosted by Jennifer Kim of Cantor, and Swayampakula Ramakanth, PhD, of H.C.
More Precigen Inc News

Company Profile

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The firm focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. It operates through the following segments: PGEN Therapeutics, ActoBio, MBP Titan, Trans Ova and All Other. The PGEN Therapeutics segment is advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders and infectious diseases. The ActoBio segment involves in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The MBP Titan segment comprises of Methane Bioconversion Platform, and associated technologies, personnel, and facilities The Trans Ova segment includes provides advanced reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Head office United States
CEO Helen Sabzevari
Employees 143
Founded 1998
Website precigen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today